로딩 중…
지수 로딩 중…
이글벳
044960· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩3,125+0.48%
2026-09-18
Financials
Valuation Metrics
이글벳's Market Cap is ₩395B. At end of 2025 it was ₩529B. Ranked #1908 of 2,421 in KR market (top 79%), #1188 of 1,640 on KOSDAQ (top 72%), #203 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 88%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 39.51B KRW | KR#1,908/2,421 Sec#203/231 |
| Revenue | 44.73B KRW | KR#1,853/2,421 Sec#129/231 |
| Net Income | 5.45B KRW | KR#1,174/2,421 Sec#76/231 |
| Total Assets | 67.78B KRW | KR#2,038/2,421 Sec#172/231 |
| Net Assets | 54.68B KRW | KR#1,846/2,421 Sec#156/231 |
| Employees | 110 | KR#1,574/2,421 Sec#123/231 |
| Value | ||
| P/E | 7.24x | KR#589/2,421 Sec#26/231 |
| P/B | 0.72x | KR#1,161/2,421 Sec#67/231 |
| PEG | 0.12x | KR#455/2,421 Sec#24/231 |
| P/S | 0.88x | KR#1,302/2,421 Sec#76/231 |
| EV/EBITDA | 9.35x | KR#578/2,421 Sec#25/231 |
| Profitability | ||
| ROE | 9.97% | KR#616/2,421 Sec#43/231 |
| ROA | 8.05% | KR#436/2,421 Sec#33/231 |
| Op. Margin | 10.01% | KR#521/2,421 Sec#46/231 |
| Revenue Growth | 6.68% | KR#1,092/2,421 Sec#106/231 |
| Earnings Growth | 58.15% | KR#517/2,421 Sec#35/231 |
| Financial Health | ||
| Debt Ratio | 23.95% | KR#465/2,421 Sec#55/231 |
| Total Debt | 8.47B KRW | KR#1,679/2,421 Sec#154/231 |
| Cash | 6.11B KRW | KR#1,927/2,421 Sec#171/231 |
| Current Ratio | 3.67x | KR#432/2,421 Sec#65/231 |
| Net Debt/EBITDA | 0.53x | KR#678/2,421 Sec#41/231 |
| Dividend | ||
| Div. Yield | 2.56% | KR#736/2,421 Sec#36/231 |
| Div. Growth | 33.33% | KR#328/2,421 Sec#17/231 |
| Performance | ||
| 1Y Return | -27.49% | KR#1,482/2,421 Sec#113/231 |
| 1M Return | 1.96% | KR#1,030/2,421 Sec#77/231 |
| From 52W High | -35.43% | KR#726/2,421 Sec#48/231 |
| 1Y MDD | -38.56% | KR#532/2,421 Sec#37/231 |
| Trading | ||
| Volume | 10,310 shares | KR#1,901/2,421 Sec#185/231 |
| Trading Value | 32.1M KRW | KR#2,000/2,421 Sec#204/231 |
| Foreign Own. | 2.32% | KR#1,516/2,421 Sec#142/231 |
| Per Share | ||
| EPS | 431 KRW | KR#1,046/2,421 Sec#72/231 |
| BPS | 4,326 KRW | KR#1,604/2,421 Sec#114/231 |
Company Info
Iglobet, established in 1983, manufactures, imports, and sells animal pharmaceuticals for major livestock species, while also developing new businesses in pet pharmaceuticals, feed, and accessories. The company, which was listed on KOSDAQ in 2000, obtained EU GMP certification for sterile injectable drugs in 2017, establishing a foothold for European exports. It employs a sales strategy that shares profits with distributors through its SD policy. Iglobet is headquartered in Yesan-gun, Chungcheongnam-do.